Michiel S van der Heijden

23PUBLICATIONS
227CO-AUTHORS
Predictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Liquid biopsiesApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Cancer genetics
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (23)

|Sep 17, 2026
Pre-existing immunity and hrHPV status determine immunotherapy response in advanced penile cancer: biomarkers and overall survival in the PERICLES trial.

|Jun 17, 2026
Tremelimumab with or without durvalumab in combination with paclitaxel in metastatic urothelial cancer: phase I/II ICRA trial.

|Feb 27, 2026
Ipilimumab and nivolumab followed by chemoradiotherapy as bladder-sparing treatment in muscle-invasive bladder cancer: a phase 2 trial.

Jan-Jaap J Mellema, Chantal F Stockem, Cameron Herberts

|Dec 13, 2025
Advanced Urologic Cancer Consensus Conference (AUC3) 2025: Expert consensus on the management of renal cell and urinary tract cancers.

Rana R McKay, Sumanta Pal, Wanling Xie

|Jul 30, 2025
TAR-200 for Bacillus Calmette-Guérin-Unresponsive High-Risk Non-Muscle-Invasive Bladder Cancer: Results From the Phase IIb SunRISe-1 Study.

Siamak Daneshmand, Michiel S Van der Heijden, Joseph M Jacob

|Jun 24, 2025
The rapidly evolving paradigm of neoadjuvant immunotherapy across cancer types.

Gil Awada, Tina Cascone, Michiel S van der Heijden

Pageof 4

Frequent Collaborators

7 joint publications

Alberto Gil-Jimenez

6 joint publications

Erik Hooijberg

6 joint publications

Lodewyk F A Wessels

6 joint publications

Jeroen Van Dorp